Citigroup initiated coverage on BioNTech with a new price target
$BNTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Citigroup initiated coverage of BioNTech with a rating of Buy and set a new price target of $145.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/5/2025 | $134.00 → $145.00 | Buy | H.C. Wainwright |
| 5/29/2025 | $110.00 | Neutral | Goldman |
| 3/13/2025 | $145.00 | Buy | Citigroup |
| 1/10/2025 | $172.00 | Buy | Truist |
| 12/11/2024 | $170.00 | Overweight | Wells Fargo |
| 12/2/2024 | Outperform | BMO Capital Markets | |
| 11/19/2024 | $130.00 | Buy | Berenberg |
| 11/19/2024 | $110.00 → $125.00 | In-line → Outperform | Evercore ISI |
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next key milestone in the execution of its oncology strategy Acquisition of CureVac will complement BioNTech's capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares ("ADSs"), representing a premium of 55% to CureVac's three-month volume weighted average price of approx. $3.53 as of June 11, 2025All-stock acquisition has potential to create
BNT327, BioNTech's PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor types The co-development and co-commercialization collaboration with a 50/50 profit/loss split will leverage both partners' expertise, resources and global footprint to accelerate BNT327's path towards potential regulatory approvals and market launches BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types BioNTech SE (NASDAQ:BNTX, "BioNTech")) and B
Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA cancer immunotherapies Presented multiple clinical updates across oncology pipeline underlining BioNTech's combination strategy in oncology with first data presented for the novel combination of BNT327 plus antibody-drug conjugates ("ADCs") Development and commercial preparation for a 2025/2026 season variant-adapted COVID-19 vaccine First quarter 2025 revenues of €0.2 billion2, net loss of €0.4 billion and basic and diluted loss per share of €1.73 ($1.823) Maintained strong financial positio
H.C. Wainwright reiterated coverage of BioNTech with a rating of Buy and set a new price target of $145.00 from $134.00 previously
Goldman initiated coverage of BioNTech with a rating of Neutral and set a new price target of $110.00
Citigroup initiated coverage of BioNTech with a rating of Buy and set a new price target of $145.00
6-K - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)